Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages.
Elevated plasma levels of lipoprotein(a), Lp(a), represent a major, inherited risk factor for coronary heart disease, although the mechanism of its action remains unknown. Lp(a) is distinguished from the related LDL particle by the addition of apolipoprotein(a), apo(a). The presence of this large glycoprotein is likely to affect the binding of the particle to the LDL receptor and/or other receptors which may contribute to the atherogenic potential of Lp(a). Here we demonstrate the binding to macrophages of Lp(a) and pure recombinant apo(a) protein, via a specific, high-affinity receptor. This binding could lead to foam cell formation and the localization of Lp(a) to atherosclerotic plaques.
Zioncheck
T F
TF
Department of Cardiovascular Research, Genetech, Inc., South San Francisco, California 94080.
Powell
L M
LM
Rice
G C
GC
Eaton
D L
DL
Lawn
R M
RM
D000818:Animals; D001053:Apolipoproteins / Q000378:metabolism*; D001692:Biological Transport; D002460:Cell Line; D004705:Endocytosis; D005434:Flow Cytometry; D006801:Humans; D066298:In Vitro Techniques; D017270:Lipoprotein(a); D008074:Lipoproteins / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000378:metabolism; D008247:Lysosomes / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism*; D051379:Mice; D011994:Recombinant Proteins / Q000378:metabolism
D001053:Apolipoproteins; D017270:Lipoprotein(a); D008074:Lipoproteins; D008077:Lipoproteins, LDL; D011994:Recombinant Proteins; C032629:acetyl-LDL